Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 μg or 30 μg) and levonorgestrel (100 μg or 150 μg) on lipoprotein metabolism

Contraception

Volumn 69, Issue 2, 2004, Pages 105-113

  Scharnagl, Hubert ^a   Petersen, Gudula ^b   Nauck, Matthias ^c   Teichmann, Alexander T ^b   Wieland, Heinrich ^d   März, Winfried ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Wyeth Pharma GmbH   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apolipoprotein E; Cholesterol; Oral contraceptives; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEIOS; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONAL CONTRACEPTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MENSTRUAL CYCLE; NORMAL HUMAN; ORAL CONTRACEPTION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0842324636     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.10.004     Document Type: Article

References (34)

1. Meade T.W., Haines A.P., North W.R., et al. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet. 2:1977;948-951.
2. Fotherby K., Caldwell A.D. New progestogens in oral contraception. Contraception. 49:1994;1-32.
3. Tikkanen M.J., Nikkila E.A. Oral contraceptives and lipoprotein metabolism. J Reprod Med. 31:1986;898-905.
4. Krauss R.M., Burkman R.T. The metabolic impact of oral contraceptives. Am J Obstet Gynecol. 167:1992;1177-1184.
5. Janaud A., Rouffy J., Upmalis D., Dain M.P. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand Suppl. 156:1992;33-38.
6. Notelovitz M., Feldman E.B., Gillespy M., Gudat J. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives a controlled, comparative, 12-month clinical trial . Am J Obstet Gynecol. 160:1989;1269-1280.
7. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 325:1991;373-381.
8. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 3:1996;213-219.
9. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism key pathways involving cell-surface heparin sulfate proteoglycans and apolipoprotein E . J Lipid Res. 40:1999;1-16.
10. Seman L.J., McNamara J.R., Schaefer E.J. Lipoprotein(a), homocysteine, and remnantlike particles emerging risk factors . Curr Opin Cardiol. 14:1999;186-191.
11. Brill K., Then A., Beisiegel U., et al. Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial. Contraception. 54:1996;291-297.
12. Young R.L., DelConte A. Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels a twenty-four month clinical trial . Am J Obstet Gynecol. 181:1999;59-62.
13. Gevers Leuven J.A., Dersjant-Roorda M.C., Helmerhorst F.M., et al. Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism. Am J Obstet Gynecol. 163:1990;358-362.
14. Bloemenkamp K.W.M., Helmerhorst F.M., Dersjant-Roorda M.C. A comparative clinical investigation of two low-dose oral contraceptives containing either 75 μg gestodene or 150 μg desogestrel combined with 20 μg ethinylestradiol effect on hemostasis, lipid metabolism and carbohydrate metabolism . Gynecol Endocrinol. 12:(Suppl):1998;21-30.
15. Teichmann A. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Int J Fertil Menopausal Stud. 40:(Suppl 2):1995;98-104.
16. Agerholm-Larsen B., Nordestgaard B.G., Steffensen R., Jensen G., Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 101:2000;1907-1912.
17. Andersen R.V., Wittrup H.H., Tybjaerg-Hansen A., et al. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease the Copenhagen City Heart Study . J Am Coll Cardiol. 41:2003;1972-1982.
18. Dugi K.A., Brandauer K., Schmidt N., et al. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation. 104:2001;3057-3062.
19. Mezdour H., Jones R., Dengremont C., Castro G., Maeda N. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem. 272:1997;13570-13575.
20. Kaplan J.R., Adams M.R., Anthony M.S., et al. Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Arterioscler Thromb Vasc Biol. 15:1995;2094-2100.
21. Croft P., Hannaford P.C. Risk factors for acute myocardial infarction in women evidence from the Royal College of General Practitioners' oral contraception study . Br Med J. 298:1989;165-168.
22. Thorogood M., Vessey M.P. An epidemiologic survey of cardiovascular disease in women taking oral contraceptives. Am J Obstet Gynecol. 163:1990;274-281.
23. Stampfer M.J., Willett W.C., Colditz G.A., Speizer F.E., Hennekens C.H. Past use of oral contraceptives and cardiovascular disease a meta-analysis in the context of the Nurses' Health Study . Am J Obstet Gynecol. 163:1990;285-291.
24. Greenlund K.J., Webber L.S., Srinivasan S., et al. Associations of oral contraceptive use with serum lipids and lipoproteins in young women the Bogalusa Heart Study . Ann Epidemiol. 7:1997;561-567.
25. Jick H., Jick S., Myers M.W., Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet. 347:1996;627-628.
26. Lewis M.A., Spitzer W.O., Heinemann L.A., et al. Third generation oral contraceptives and risk of myocardial infarction an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women . BMJ. 312:1996;88-90.
27. Lewis M.A., Heinemann L.A., Spitzer W.O., MacRae K.D., Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception. 56:1997;129-140.
28. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997;349:1202-9.
29. Dunn N., Thorogood M., Faragher B., et al. Oral contraceptives and myocardial infarction results of the MICA case-control study . BMJ. 318:1999;1579-1583.
30. Tanis B.C., van den Bosch M.A., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 345:2001;1787-1793.
31. Kuhl H., Marz W., Jung-Hoffmann C., et al. Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive divergent changes in apolipoprotein B and E and transitory decrease in Lp(a) levels . Contraception. 47:1993;69-83.
32. Porkka K.V., Erkkola R., Taimela S., et al. Influence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors. Ann Med. 27:1995;193-198.
33. Shlipak M.G., Simon J.A., Vittinghoff E., et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 283:2000;1845-1852.
34. Nguyen TT, Hodge DO, Lohse CM, Heshamati HM. Postmenopausal hormone replacement therapy, lipoprotein (a) and coronary heart disease events in a cohort of 2,853 healthy women. Circulation 2000;102(Suppl):Abstract No. 4022.